Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Roudier MP, et al. Clin Exp Metastasis. 2003;20(2):171-80. doi: 10.1023/a:1022627421000. Clin Exp Metastasis. 2003. PMID: 12705638
A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone.
Hesami P, Holzapfel BM, Taubenberger A, Roudier M, Fazli L, Sieh S, Thibaudeau L, Gregory LS, Hutmacher DW, Clements JA. Hesami P, et al. Clin Exp Metastasis. 2014 Apr;31(4):435-46. doi: 10.1007/s10585-014-9638-5. Epub 2014 Feb 8. Clin Exp Metastasis. 2014. PMID: 24510218
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C. Haider M, et al. Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14. Clin Exp Metastasis. 2016. PMID: 26667932 Free PMC article.
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. Canon J, et al. Breast Cancer Res Treat. 2012 Oct;135(3):771-80. doi: 10.1007/s10549-012-2222-2. Epub 2012 Aug 29. Breast Cancer Res Treat. 2012. PMID: 22926264
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC. Holland PM, et al. Cancer Biol Ther. 2010 Apr 1;9(7):539-50. doi: 10.4161/cbt.9.7.11266. Epub 2010 Apr 1. Cancer Biol Ther. 2010. PMID: 20150760
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Canon JR, et al. Clin Exp Metastasis. 2008;25(2):119-29. doi: 10.1007/s10585-007-9127-1. Epub 2007 Dec 5. Clin Exp Metastasis. 2008. PMID: 18064531
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. Miller RE, et al. Mol Cancer Ther. 2008 Jul;7(7):2160-9. doi: 10.1158/1535-7163.MCT-08-0046. Epub 2008 Jul 7. Mol Cancer Ther. 2008. PMID: 18606716
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.
Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC. Canon J, et al. Bone. 2010 Jun;46(6):1613-9. doi: 10.1016/j.bone.2010.03.001. Epub 2010 Mar 6. Bone. 2010. PMID: 20215062
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series.
Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL. Morrissey C, et al. Among authors: roudier mp. J Bone Miner Res. 2013 Feb;28(2):333-40. doi: 10.1002/jbmr.1749. J Bone Miner Res. 2013. PMID: 22936276 Free PMC article.
21 results
Jump to page